drugset / Trial / NCT01214278
Bioavailability of Different n-3 Fatty Acid Formulations
RandomizedCrossoverOpen-labelPrevention
Summary
The aim of this study is to examine differences in short term bioavailability between four n-3 FA formulations in healthy males.
Timeline
- Start
- 2010-10
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EE [arm: experimental] — EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA) | Unknown | 2016 mg | — |
| Subject | GArTG | Unknown | 2016 mg | — |
| Subject | KPL | Unknown | 2100 mg | — |
| Subject | rTG | Unknown | 2016 mg | — |
Indications
No indication recorded.